Testing a blood marker for fatty liver disease
Part of Digestive system clinical trials.
This trial is testing whether a substance in the blood called pro-neurotensin can help diagnose MASLD (a type of fatty liver disease not caused by alcohol). Participants will have a blood test and an abdominal ultrasound to see if this marker can identify fatty liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You do not drink alcohol.
- You have not been diagnosed with other liver diseases such as hepatitis, autoimmune liver disease, or Wilson's disease.
- You are not taking any medications or herbal supplements that could affect your liver.
- You are willing to have a blood test and an abdominal ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
This study tests a new, non-invasive way to diagnose a type of fatty liver disease (MASLD) in children with obesity. It aims to find simple blood or imaging markers that can detect the condition without a liver biopsy.
Hear when a new Steatosis of Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.